New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 5, 2014
08:38 EDTENTAEnanta Pharmaceuticals ABT-493 has potential, says JMP Securities
After examining data on Enanta's protease inhibitor, ABT-493. JMP Securities is encouraged by the drug's potential, as the firm thinks it can be competitive in the HCV space. The firm reiterates a $50 price target and Outperform rating on the shares.
News For ENTA From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
June 30, 2015
07:33 EDTENTAEnanta appoints Nathalie Adda as SVP, chief medical officer
Enanta Pharmaceuticals (ENTA) announced the appointment of Nathalie Adda, M.D., as senior VP and chief medical officer, responsible for clinical and regulatory affairs. Most recently, Adda was chief medical officer, VP Clinical Development, Medical and Regulatory Affairs at Transgene (TRNG), where she led the Oncology and Infectious Disease programs since 2012.
June 22, 2015
08:56 EDTENTAEnanta management to meet with JPMorgan
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use